Differential effects of thapsigargin analogues on apoptosis of prostate cancer cells: Complex regulation by intracellular calcium

FEBS Journal

Volumn 280, Issue 21, 2013, Pages 5430-5440

  Dubois, Charlotte ^a,b   Vanden Abeele, Fabien ^a   Sehgal, Pankaj ^b,c   Lesen, Claus ^b,c   Junker, Steffen ^c   Christensen, Søren B ^d   Prevarskaya, Natalia ^a   Møller, Jesper V ^b,c  

^a Université des Sciences et Technologies de Lille   (France)

^b Danish Research Foundation   (Denmark)

^c AARHUS UNIVERSITY   (Denmark)

^d UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

apoptosis; calcium; prostate cancer; SERCA; thapsigargin analogue

Indexed keywords

ANDROGEN; ANTINEOPLASTIC AGENT; ASPARTIC ACID; CALCIUM; LEUCINE; SARCOPLASMIC RETICULUM CALCIUM TRANSPORTING ADENOSINE TRIPHOSPHATASE; THAPSIGARGIN; THAPSIGARGIN DERIVATIVE; UNCLASSIFIED DRUG;

APOPTOSIS; CALCIUM CELL LEVEL; CALCIUM DEPLETION; CALCIUM MOBILIZATION; CALCIUM TRANSPORT; CANCER CELL; CELL STRAIN LNCAP; CELL STRUCTURE; CELL VIABILITY; CHEMOSENSITIVITY; CONCENTRATION RESPONSE; CONFERENCE PAPER; CONTROLLED STUDY; CYTOSOL; DRUG DESIGN; DRUG EFFECT; ENDOPLASMIC RETICULUM STRESS; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROSTATE CANCER; REGULATORY MECHANISM;

APOPTOSIS; CALCIUM; PROSTATE CANCER; SERCA; THAPSIGARGIN ANALOGUE;

APOPTOSIS; CALCIUM; CALCIUM CHANNELS; CELL MEMBRANE; CELL PROLIFERATION; CYTOSOL; ENZYME INHIBITORS; HUMANS; ION TRANSPORT; MALE; PROSTATIC NEOPLASMS; SARCOPLASMIC RETICULUM CALCIUM-TRANSPORTING ATPASES; THAPSIGARGIN; TUMOR CELLS, CULTURED;

EID: 84886095138     PISSN: 1742464X     EISSN: 17424658     Source Type: Journal    
DOI: 10.1111/febs.12475     Document Type: Conference Paper

References (25)

1. Denmeade SR, &, Isaacs JT, (2005) The SERCA pump as a therapeutic target: making a 'smart bomb' for prostate cancer. Cancer Biol Ther 4, 14-22.
2. Berridge MJ, Bootman MD, &, Roderick HL, (2003) Calcium signalling: dynamics, homeostasis and remodelling. Nat Rev Mol Cell Biol 4, 517-529.
3. Denmeade SR, Jakobsen CM, Janssen S, Khan SR, Garrett ES, Lilja H, Christensen SB, &, Isaacs JT, (2003) Prostate-specific antigen-activated thapsigargin prodrug as targeted therapy for prostate cancer. J Natl Cancer Inst 95, 990-1000.
4. Rasmussen U, Christensen SB, &, Patkar SA, (1982) Structure and biological activity of sesquiterpene lactones from thapsia species and of analogue derivatives. Planta Med 45, 157.
5. 2+-ATPase. Proc Natl Acad Sci USA 87, 2466-2470.
6. Sagara Y, Wade JB, &, Inesi G, (1992) A conformational mechanism for formation of a dead-end complex by the sarcoplasmic reticulum ATPase with thapsigargin. J Biol Chem 267, 1286-1292.
7. Tombal B, Weeraratna AT, Denmeade SR, &, Isaacs JT, (2000) Thapsigargin induces a calmodulin/calcineurin-dependent apoptotic cascade responsible for the death of prostatic cancer cells. Prostate 43, 303-317.
8. 2+ current in human prostate cancer LNCaP cells: involvement in apoptosis. J Physiol 527 (Pt 1), 71-83.
9. Flourakis M, Lehen'kyi V, Beck B, Raphaël M, Vandenberghe M, Abeele FV, Roudbaraki M, Lepage G, Mauroy B, Romanin C, et al,. (2010) Orai1 contributes to the establishment of an apoptosis-resistant phenotype in prostate cancer cells. Cell Death Dis 1, e75.
10. Denmeade SR, Lou W, Lövgren J, Malm J, Lilja H, &, Isaacs JT, (1997) Specific and efficient peptide substrates for assaying the proteolytic activity of prostate-specific antigen. Cancer Res 57, 4924-4930.
11. Gupta A, Lilja H, &, Schroeder FH, (2011) Detection of prostate cancer. In Recent Advances in Prostate Cancer (, Tindall DJ, &, Scardino PT, eds), pp. 283-334. World Scientific, Singapore.
12. Denmeade SR, Mhaka AM, Rosen DM, Brennen WN, Dalrymple S, Dach I, Olesen C, Gurel B, Demarzo AM, Wilding G, et al,. (2012) Engineering a prostate-specific membrane antigen-activated tumor endothelial cell prodrug for cancer therapy. Sci Transl Med 4, 140ra86.
13. Søhoel H, Jensen A-ML, Møller JV, Nissen P, Denmeade SR, Isaacs JT, Olsen CE, &, Christensen SB, (2006) Natural products as starting materials for development of second-generation SERCA inhibitors targeted towards prostate cancer cells. Bioorg Med Chem 14, 2810-2815.
14. 2+-ATPase with thapsigargin and thapsigargin analogues. J Biol Chem 285, 28883-28892.
15. Deng X, Wang Y, Zhou Y, Soboloff J, &, Gill DL, (2009) STIM and Orai: dynamic intermembrane coupling to control cellular calcium signals. J Biol Chem 284, 22501-22505.
16. 2+ channels with different activation modes and molecular origin in LNCaP human prostate cancer epithelial cells. J Biol Chem 279, 30326-30337.
17. Axelsen KB, &, Palmgren MG, (1998) Evolution of substrate specificities in the P-type ATPase superfamily. J Mol Evol 46, 84-101.
18. Pomorski T, &, Menon AK, (2006) Lipid flippases and their biological functions. Cell Mol Life Sci 63, 2908-2921.
19. Suzuki J, Umeda M, Sims PJ, &, Nagata S, (2010) Calcium-dependent phospholipid scrambling by TMEM16F. Nature 468, 834-838.
20. Vander Griend DJ, Antony L, Dalrymple SL, Xu Y, Christensen SB, Denmeade SR, &, Isaacs JT, (2009) Amino acid containing thapsigargin analogues deplete androgen receptor protein via synthesis inhibition and induce the death of prostate cancer cells. Mol Cancer Ther 8, 1340-1349.
21. Schwarze SR, Lin EW, Christian PA, Gayheart DT, &, Kyprianou N, (2008) Intracellular death platform steps-in: targeting prostate tumors via endoplasmic reticulum (ER) apoptosis. Prostate 68, 1615-1623.
22. Chin TY, Lin HC, Kuo JP, &, Chueh SH, (2007) Dual effect of thapsigargin on cell death in porcine aortic smooth muscle cells. Am J Physiol Cell Physiol 292, C383-395.
23. 2+)-activated ATPase from sarcoplasmic reticulum. Effect of protein-protein interactions. J Biol Chem 255, 1912-1920.
24. 2+ indicators with greatly improved fluorescence properties. J Biol Chem 260, 3440-3450.
25. Ní Ainle F, O'Donnell JS, Johnson JA, Brown L, Gleeson EM, Smith OP, &, Preston RJS, (2011) Activated protein C N-linked glycans modulate cytoprotective signaling function on endothelial cells. J Biol Chem 286, 1323-1330.